CN116474058A - Traditional Chinese medicine ointment for treating spleen enlargement - Google Patents
Traditional Chinese medicine ointment for treating spleen enlargement Download PDFInfo
- Publication number
- CN116474058A CN116474058A CN202310448182.8A CN202310448182A CN116474058A CN 116474058 A CN116474058 A CN 116474058A CN 202310448182 A CN202310448182 A CN 202310448182A CN 116474058 A CN116474058 A CN 116474058A
- Authority
- CN
- China
- Prior art keywords
- parts
- vinegar
- traditional chinese
- chinese medicine
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims description 80
- 210000000952 spleen Anatomy 0.000 title abstract description 39
- 206010041660 Splenomegaly Diseases 0.000 claims abstract description 42
- 235000021419 vinegar Nutrition 0.000 claims abstract description 36
- 239000000052 vinegar Substances 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 17
- 229940116229 borneol Drugs 0.000 claims abstract description 17
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000010446 mirabilite Substances 0.000 claims abstract description 17
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 17
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 16
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 16
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 16
- 240000004980 Rheum officinale Species 0.000 claims abstract description 10
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 10
- 241000237502 Ostreidae Species 0.000 claims abstract description 9
- 235000020636 oyster Nutrition 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 235000008113 selfheal Nutrition 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 20
- 235000019198 oils Nutrition 0.000 claims description 20
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 240000009138 Curcuma zedoaria Species 0.000 claims description 11
- 239000011505 plaster Substances 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 10
- 241000329195 Sparganium erectum Species 0.000 claims description 10
- 235000005272 common selfheal Nutrition 0.000 claims description 10
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 10
- 235000019509 white turmeric Nutrition 0.000 claims description 10
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000008159 sesame oil Substances 0.000 claims description 8
- 235000011803 sesame oil Nutrition 0.000 claims description 8
- 229940078465 vanillyl butyl ether Drugs 0.000 claims description 8
- 241000219061 Rheum Species 0.000 claims description 7
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 7
- 206010019799 Hepatitis viral Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000001862 viral hepatitis Diseases 0.000 claims description 5
- 239000012790 adhesive layer Substances 0.000 claims description 4
- 230000000181 anti-adherent effect Effects 0.000 claims description 4
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- 239000000779 smoke Substances 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 230000007480 spreading Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- 230000036407 pain Effects 0.000 abstract description 14
- 208000002193 Pain Diseases 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 description 23
- 238000003745 diagnosis Methods 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 210000003240 portal vein Anatomy 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- 235000008216 herbs Nutrition 0.000 description 8
- 208000006083 Hypokinesia Diseases 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 206010019847 hepatosplenomegaly Diseases 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 210000000955 splenic vein Anatomy 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960000980 entecavir Drugs 0.000 description 3
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- -1 glycyrrhizic acid diamine Chemical class 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 25-35 parts of vinegar rhizoma sparganii, 25-35 parts of vinegar rhizoma curcumae, 25-35 parts of radix trichosanthis, 25-35 parts of selfheal, 25-35 parts of calcined oyster, 15-25 parts of mirabilite, 15-25 parts of cassia twig, 5-15 parts of rheum officinale and 5-15 parts of borneol; the invention has scientific and reasonable compatibility of components, abundant raw materials and simple preparation method, has the effects of activating blood circulation to dissipate blood stasis, softening and resolving hard mass, reducing swelling and relieving pain, can effectively control the size of spleen, obviously improves uncomfortable symptoms of patients, relieves pains of the patients, and has remarkable social and economic benefits.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine ointment for treating splenomegaly.
Background
Common causes of splenomegaly include infectious and non-infectious, and are commonly found in acute infections such as bacterial/viral/parasitic infections, chronic viral hepatitis, cirrhosis, hematopathy, connective tissue disease, schistosomiasis, malaria, and the like. Patients with chronic viral hepatitis and early stage liver cirrhosis have increased levels of various collagens in the liver, such as type I and iii collagen deposition, and mild splenomegaly, which can be reversed if positively treated. The spleen is normally not accessible under the rib, but is only accessible when the viscera sags or the diaphragm descends or inhales deeply, but does not exceed 1cm under the rib and has a softer texture.
At present, modern medicine mainly treats primary focus, surgical excision treatment, spleen arterial embolism and other symptomatic support treatment for treating splenomegaly, but the cause of the disease is unknown in many cases, and radical treatment is difficult, and sometimes even if the cause of the disease is clear, such as hepatitis B, fatty liver, alcoholic liver and the like, the disease can continue to progress forward due to limited treatment methods, so that advanced liver cirrhosis and even liver cancer occur. Therefore, western medicine has a limited effect on treating splenomegaly.
The combination of the syndrome differentiation and the diagnosis and treatment of the traditional Chinese medicine emphasizes the individual treatment, has stronger pertinence, obvious curative effect, small toxic and side effect and adverse reaction, is easy to be accepted by patients, and plays a positive role in the treatment of splenomegaly due to the characteristics of simplicity, convenience and low efficiency of the external treatment method of the traditional Chinese medicine. In the prior art, although the spleen is clinically researched according to the principle of dialectical treatment, various traditional Chinese medicines for treating spleen enlargement are developed, for example, CN107961346A discloses a Chinese herbal medicine foot soaking liquid for treating hepatosplenomegaly; CN103432519B discloses a traditional Chinese medicine for treating chronic hepatitis and hepatosplenomegaly due to liver cirrhosis; CN107050252a discloses a traditional Chinese medicine for treating hepatosplenomegaly and a preparation method thereof; CN103977283a discloses a traditional Chinese medicine oral liquid for treating hepatosplenomegaly; CN101732423a discloses a traditional Chinese medicine pill for treating hepatosplenomegaly; CN102100787a discloses a traditional Chinese medicine for treating hepatosplenomegaly and the like. However, the cause of splenomegaly is many, and its clinical therapeutic effect is not exact, and the size of spleen cannot be controlled effectively. Therefore, there is a need to develop a traditional Chinese medicine for treating splenomegaly, which aims at the splenomegaly caused by liver cirrhosis compensatory period and chronic viral hepatitis, but has not been reported in public so far.
Disclosure of Invention
Aiming at the situation, the invention aims to overcome the defects of the prior art and provide the traditional Chinese medicine ointment for treating splenomegaly, which can effectively solve the problems of inaccurate clinical treatment effect and unobvious effect of the traditional Chinese medicine for treating splenomegaly.
In order to achieve the aim, the technical scheme is that the traditional Chinese medicine ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 25-35 parts of vinegar rhizoma sparganii, 25-35 parts of vinegar rhizoma curcumae, 25-35 parts of radix trichosanthis, 25-35 parts of selfheal, 25-35 parts of calcined oyster, 15-25 parts of mirabilite, 15-25 parts of cassia twig, 5-15 parts of rheum officinale and 5-15 parts of borneol; the raw materials are uniformly mixed, and the traditional Chinese medicine composition comprises the following components in percentage by mass of 3.5:10:0.2:0.025 sesame oil, azelastone and vanillyl butyl ether are taken, firstly, the sesame oil is heated to 200 ℃ to 220 ℃, then the traditional Chinese medicine composition is added for extracting the medicine materials, the medicine is decocted until the appearance is dark brown and the interior is brown, the medicine residues are fished out, and the medicine oil is continuously heated and decocted until the temperature is 280 ℃ to 320 ℃ and the medicine oil is formed into beads by dripping water; adding red lead into the medicinal oil at uniform speed, wherein the mass ratio of the medicinal oil to the red lead is (10): 3-4, slowly pouring the mixture into cold water to soak for three days and days after the white thick smoke is exhausted and the red color disappears and the oil color changes from brown to black brown, changing water once a day to remove fire toxin, and obtaining plaster blocks; placing the plaster block into a container, heating with slow fire to 60-70deg.C, sequentially adding azepinone and vanillyl butyl ether, heating under stirring, spreading on non-woven fabric, and covering with anti-adhesive layer.
The invention has scientific and reasonable compatibility of components, abundant raw materials and simple preparation method, has the effects of activating blood circulation to dissipate blood stasis, softening and resolving hard mass, reducing swelling and relieving pain, can effectively control the size of spleen, obviously improves uncomfortable symptoms of patients, relieves pains of the patients, and has remarkable social and economic benefits.
Detailed Description
The following describes specific embodiments of the present invention in detail with reference to examples and specific cases.
The invention may be embodied by the following examples.
Example 1
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 28-33 parts of vinegar common burreed rhizome, 28-33 parts of vinegar zedoary, 28-33 parts of radix trichosanthis, 28-33 parts of common selfheal fruit-spike, 28-33 parts of calcined oyster shell, 18-22 parts of mirabilite, 18-22 parts of cassia twig, 8-11 parts of rhubarb and 8-11 parts of borneol; the raw materials are uniformly mixed, and the traditional Chinese medicine composition comprises the following components in percentage by mass of 3.5:10:0.2:0.025 sesame oil, azelastone and vanillyl butyl ether are taken, firstly, the sesame oil is heated to 200 ℃ to 220 ℃, then the traditional Chinese medicine composition is added for extracting the medicine materials, the medicine is decocted until the appearance is dark brown and the interior is brown, the medicine residues are fished out, and the medicine oil is continuously heated and decocted until the temperature is 280 ℃ to 320 ℃ and the medicine oil is formed into beads by dripping water; adding red lead into the medicinal oil at uniform speed, wherein the mass ratio of the medicinal oil to the red lead is (10): 3-4, slowly pouring the mixture into cold water to soak for three days and days after the white thick smoke is exhausted and the red color disappears and the oil color changes from brown to black brown, changing water once a day to remove fire toxin, and obtaining plaster blocks; placing the plaster block into a container, heating with slow fire to 60-70deg.C, sequentially adding azepinone and vanillyl butyl ether, heating under stirring, spreading on non-woven fabric, and covering with anti-adhesive layer.
Example 2
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 25 parts of vinegar common burreed rhizome, 25 parts of vinegar zedoary, 25 parts of radix trichosanthis, 25 parts of common selfheal fruit-spike, 25 parts of calcined oyster shell, 15 parts of mirabilite, 15 parts of cassia twig, 5 parts of rheum officinale and 5 parts of borneol.
Example 3
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 28 parts of vinegar rhizoma sparganii, 28 parts of vinegar rhizoma curcumae, 28 parts of radix trichosanthis, 28 parts of selfheal, 28 parts of calcined oyster, 18 parts of mirabilite, 18 parts of cassia twig, 8 parts of rheum officinale and 8 parts of borneol.
Example 4
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 30 parts of vinegar common burreed rhizome, 30 parts of vinegar zedoary, 30 parts of radix trichosanthis, 30 parts of common selfheal fruit-spike, 30 parts of calcined oyster shell, 20 parts of mirabilite, 20 parts of cassia twig, 10 parts of rheum officinale and 10 parts of borneol.
Example 5
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 33 parts of vinegar common burreed rhizome, 33 parts of vinegar zedoary, 33 parts of radix trichosanthis, 33 parts of common selfheal fruit-spike, 33 parts of calcined oyster shell, 23 parts of mirabilite, 23 parts of cassia twig, 13 parts of rhubarb and 13 parts of borneol.
Example 6
A Chinese medicinal ointment for treating splenomegaly is prepared from the following raw materials in parts by weight: 35 parts of vinegar common burreed rhizome, 35 parts of vinegar zedoary, 35 parts of radix trichosanthis, 35 parts of common selfheal fruit-spike, 35 parts of calcined oyster shell, 25 parts of mirabilite, 25 parts of cassia twig, 15 parts of rhubarb and 15 parts of borneol.
The traditional Chinese medicine used in the invention comprises the following components:
vinegar rhizoma Sparganii: san Leng is pungent, bitter and flat in property, enters liver and spleen meridians, and its actions of breaking qi stagnation and removing food retention are stronger, so it is often indicated for food stagnation and abdominal distention. San Leng after vinegar processing is added into blood system to break blood, remove stasis and soften hard mass, so it is often used for amenorrhea due to blood stasis and mass.
Vinegar rhizoma Curcumae: the curcuma zedoary has warm nature, pungent and bitter taste, enters liver and spleen meridians, has the effects of breaking blood and removing stasis, removing food retention and removing stasis, promoting qi circulation and relieving pain, and can enter blood and qi. It can promote blood circulation, remove blood stasis and relieve pain after being processed with vinegar.
Radix trichosanthis: slightly cold in nature, sweet in flavor and slightly bitter in flavor. Enter lung meridian and stomach meridian. Clearing heat and promoting fluid production, detumescence and expelling pus. Belongs to the heat-clearing herbs and belongs to the category of heat-clearing and fire-purging herbs.
Spica Prunellae: cold nature, pungent and bitter taste. It enters liver meridian and gallbladder meridian. Clearing away fire, improving eyesight, resolving hard mass, and relieving swelling. Belongs to the heat-clearing herbs and belongs to the category of heat-clearing and fire-purging herbs.
Calcined oyster: oyster is slightly cold in nature and salty in taste. It enters liver meridian, gallbladder meridian and kidney meridian. The medicine has the functions of relieving the weight of the heart and calming the nerves, suppressing yang and tonifying yin, softening hardness and resolving hard mass, and the calcined oyster has the functions of astringing and inducing astringency. Belongs to liver yang-soothing herbs belonging to the category of liver-pacifying and wind-extinguishing herbs.
Mirabilite: cold nature, salty and bitter taste. Enter stomach meridian and large intestine meridian. Purging heat, relaxing bowels, moistening dryness, softening hard masses, clearing pathogenic fire, and relieving swelling. Belongs to purgatives and purgation herbs in the category.
Ramulus Cinnamomi: pungent and sweet in flavor and warm in nature. Enter the bladder meridian, heart meridian and lung meridian. It is a pungent and warm herb that can relieve exterior syndrome, warm meridians, promote blood circulation, strengthen yang, promote qi circulation, smooth pulse and reduce qi.
Rhubarb: cold nature and bitter taste. It enters spleen meridian, stomach meridian, large intestine meridian, liver meridian and pericardium meridian. Purging heat, relaxing bowels, cooling blood, removing toxic substances, removing blood stasis, and dredging channels. Belongs to purgatives and purgation herbs in the category.
Borneol: cold nature, pungent and bitter taste. It enters heart meridian, spleen meridian and lung meridian. Inducing resuscitation, refreshing mind, clearing heat and relieving pain. Belongs to a resuscitation inducing medicine.
The formula takes rhizoma sparganii with vinegar and rhizoma curcumae with vinegar as principal drugs, activates blood circulation to remove blood stasis, moves qi to alleviate pain, ministerial drugs such as radix trichosanthis, selfheal and calcined oyster soften hardness to dissipate stagnation and detumescence, and auxiliary drugs such as rheum officinale and mirabilite to dispel hard fire, detoxify and detumescence, cassia twig dispel cold to alleviate pain, activate yang to remove qi, and the function of borneol detumescence, analgesia and transdermal absorbent is adopted, and the whole formula compatibility has the effects of activating blood circulation to remove blood stasis, softening hardness to dissipate stagnation together.
The traditional Chinese medicine composition disclosed by the invention is prepared scientifically, has stable quality and good curative effect, is strict in compatibility and complements each other according to monarch, minister, assistant and guide, and has very good beneficial technical effects through clinical experiments, and related experimental data are as follows (taking example 4 as an example):
1. case selection:
1.1 clinical data: 105 splenomegaly patients who were treated in a first affiliated hospital of Henan traditional Chinese medicine university were selected from 7 months 2021 to 7 months 2022, and were randomly divided into a control 1 group, a control 2 group and an experimental group, each group being 35 cases.
1.2 selection index:
(1) Inclusion criteria: all patients who were selected were splenomegaly patients with no serious dysfunction of heart, brain, liver and kidney, no obvious bleeding tendency and no history of drug abuse.
(2) Exclusion criteria: those who do not meet the inclusion criteria are those who are allergic to drugs, pregnant and lactating women, have history of drug abuse, and are not able to cooperate with the treatment of mental disturbance.
2. Treatment protocol:
the control 1 group is treated with the existing Chinese medicine (carapax Trionycis decoction), and the treatment course is 1 month; the control group 2 was treated with western medicine (reduced glutathione (liver protection enzyme reduction), entecavir (antiviral), and propranolol (portal vein pressure reduction) were taken according to the primary disease), and the course of treatment was 1 month; the experimental group is treated by the traditional Chinese medicine ointment disclosed in the embodiment 4 of the invention, and the ointment is applied for 1 time every 1-2 days and is continuously used for 1 month.
3. And (3) observing the indexes:
observation index and evaluation criteria:
1) Obvious effect or clinical cure: the discomfort symptoms of the patient are obviously reduced, and the upper abdomen color Doppler ultrasound examination is adopted for knowing the main trunk inner diameter, the main trunk flow velocity, the thickness, the long diameter, the internal diameter of the spleen vein and the like of the portal vein, so that the result shows that the spleen is greatly eliminated;
2) The method is effective: the discomfort symptoms of the patient are relieved, and the upper abdomen color Doppler ultrasound examination is adopted for knowing the main trunk inner diameter, the main trunk flow velocity, the thickness, the long diameter, the inner diameter of the spleen vein and the like of the portal vein, so that the result shows that the spleen size is reduced;
3) Invalidation: the discomfort symptoms of the patients are not improved, and the upper abdomen color Doppler ultrasound examination is adopted for knowing the main trunk inner diameter, the main trunk flow rate, the thickness, the long diameter, the inner diameter of the spleen vein and the like of the portal vein, so that the results show that the spleen is not improved greatly, even increased.
Total effective rate = [ (number of obvious or clinical recovery cases + number of effective cases)/total cases ] ×100%.
4. Safety evaluation:
first-order: safety and no adverse reaction;
and (2) second-stage: the medicine is safer, has adverse reaction, and can be continuously administered without any treatment;
three stages: has the safety problem and moderate adverse reaction, and can be continuously administered after treatment;
four stages: the test was discontinued due to adverse reactions.
5. And (3) test statistical treatment:
the test data are analyzed and processed by SPSS25.0 statistical software, and the difference of P < 0.05 is statistically significant. The results are shown in tables 1, 2 and 3 below:
table 1 comparison of changes in spleen thickness, major diameter and internal diameter of spleen vein after treatment of three groups of patients
Note that: delta: p < 0.05 compared with the group before treatment; #: p < 0.05 compared with the control 1 after treatment; the ∈: p < 0.05 compared to control group 2 after treatment.
Table 2 evaluation and comparison of overall efficacy after treatment for three groups of patients
Table 3 three patient safety assessments
From the above, the spleen thickness, the spleen long diameter and the spleen vein inner diameter of the patients in the experimental group are obviously reduced, 11 cases are obviously effective or healed, 19 cases are effective, the total effective rate reaches 85.7%, and adverse reactions do not occur in the experimental group.
6. Typical cases
Case 1: some male, 39 years old, the native place, run: unsealing the city, the Qixi and the peasant, and carrying out a first diagnosis on 10 months and 28 days in 2021.
Complaints: the right rib is distended and uncomfortable for more than 1 year, and the current medical history is that: the patients have symptoms of fullness and discomfort in the right hypochondrium and rib, dull complexion, hypodynamia, no attention, no special treatment and further system diagnosis and treatment in the hospital. The following symptoms: distention and discomfort in the right hypochondrium, dark complexion, hypodynamia, general sleep and normal urination and defecation. A dark red tongue with a thin and white coating, a visible sublingual vein and a wiry pulse. Checking: liver palms and spider nevi were positive. Auxiliary inspection: liver, gall, spleen and pancreas with portal vein color Doppler ultrasound prompting: cirrhosis, splenomegaly (thickness 55mm, long diameter 157mm, internal diameter of splenic vein 10 mm), liver function ALT:20.7, AST:15.9, GGT:68.1. diagnosis of traditional Chinese medicine: liver-qi stagnation and spleen-blood stasis. Western diagnosis: and B, hepatitis B liver cirrhosis compensation period.
The treatment method comprises the following steps: liver soothing, spleen strengthening, blood circulation activating, blood stasis removing, hard mass softening and resolving. A hot paste treatment 14 paste of the traditional Chinese medicine paste for treating splenomegaly described in the example 4 is prescribed, and the paste is externally applied to the spleen area, 1 paste per day.
Two diagnoses: the symptoms of the right hypochondrium, fullness and discomfort and hypodynamia of the patient are obviously improved before the 2021 is carried out on 12 months and 20 days. After half a year of use, the liver, gall, spleen and pancreas are rechecked by the portal vein color Doppler ultrasound prompt: liver cirrhosis, splenomegaly (thickness 40mm, length 143mm, internal diameter of splenic vein 7 mm), liver function is normal; after the treatment is continued for half a year, all symptoms are improved.
Case 2: somewhere, man, 42 years old, native: the first visit of the worker in Ru nan county of the standing-horse store, 4 months and 9 days in 2022.
Complaints: the left and right hypochondrium is uncomfortable for more than 1 year and aggravated for 1 week. The current medical history: the patients have discomfort of right hypochondrium and rib after 1 year and home vital energy, with abdominal distension and diarrhea, the symptoms are not obviously improved when the patients are treated by oral administration of traditional Chinese medicines to local clinics (in detail), the symptoms are repeatedly developed, the patients go to a hospital in Zhengzhou city, and the liver, gall, spleen and pancreas are added with portal color Doppler ultrasound prompt: liver cirrhosis, splenomegaly (thickness 64mm, long diameter 280mm, subcostal 87mm, internal diameter of splenic vein 17), liver function: ALT:47, TBIL:42.3 mu mol/l, five items of hepatitis B are small Sanyang, and the Entecavir dispersible tablet is antiviral, the thymus peptide enteric-coated tablet improves the immunity and the traditional Chinese medicine treatment. The symptoms of serious symptoms, slight hypodynamia, no abdominal distension and pain, nausea, gum bleeding and the like, which are caused by no obvious cause before 1 week, are solved for further system diagnosis and treatment so as to be treated in our hospital. The following symptoms: clear mind, general spirit, discomfortable right hypochondrium, slight debilitation, general sleep, normal urination and defecation, dark red tongue, bao Shao coating and wiry and thready pulse. Diagnosis of traditional Chinese medicine: liver-qi stagnation and spleen-blood stasis. Western diagnosis: hepatitis B liver cirrhosis compensating period, splenomegaly.
The treatment method comprises the following steps: liver soothing, spleen strengthening, blood circulation activating, blood stasis removing, hard mass softening and resolving. A hot paste treatment 14 paste of the traditional Chinese medicine paste for treating splenomegaly described in the example 4 is prescribed, and the paste is externally applied to the spleen area, 1 paste per day.
Two diagnoses: the symptoms of the right hypochondrium, the rib fullness and discomfort and the hypodynamia of the patient are obviously improved before the 2022 day, the 6 month and the 17 day. After half a year of use, the liver, gall, spleen and pancreas are rechecked by the portal vein color Doppler ultrasound prompt: liver cirrhosis, splenomegaly (thickness 44mm, long diameter 220mm, subcostal 60mm, internal diameter of splenic vein 13.8 mm), liver function is normal; after the treatment is continued for half a year, all symptoms are improved.
Case 3: jia somewhere, man, 54 years old, native: the first diagnosis of peasants in the city of Changku in Henan, 2022, 6 and 29 days.
Complaints: the intermittent right rib discomfort is more than 8 months. The current medical history: the patients have no obvious cause of discomfort and weakness of the right rib after 8 months, the local people's hospitals find the hepatitis B liver cirrhosis, the entecavir dispersible tablet antiviral treatment is carried out, the immunity is improved by the Zhenqi Fuzheng capsule, the liver protection and enzyme reduction treatment such as the glycyrrhizic acid diamine enteric capsule, the liver strengthening capsule and the like, so that the traditional Chinese medicine treatment is required until the clinic of our hospital is required to treat. The following symptoms: clear mind, mental condition, intermittent discomfort in the right hypochondrium, debilitation, bad smell in the mouth, insomnia, 1-2 days of stool, shaping, sticky texture and yellow urine. A dark red tongue with teeth marks on the sides, a thin, yellow and greasy coating, and a wiry and astringent pulse. Auxiliary inspection: liver, gall, spleen and pancreas with portal vein color Doppler ultrasound prompting: liver cirrhosis, splenomegaly (thickness 65mm, long diameter 168mm, internal diameter of splenic vein 12 mm), and liver function is normal. Diagnosis of traditional Chinese medicine: liver-qi stagnation and spleen-blood stasis. Western diagnosis: hepatitis B liver cirrhosis compensating period, splenomegaly.
The treatment method comprises the following steps: liver soothing, spleen strengthening, blood circulation activating, blood stasis removing, hard mass softening and resolving. A hot paste treatment 14 paste of the traditional Chinese medicine paste for treating splenomegaly described in the example 4 is prescribed, and the paste is externally applied to the spleen area, 1 paste per day.
Two diagnoses: the symptoms of the patients with distention and discomfort of the right hypochondrium and hypodynamia are obviously improved before 2022, 8 and 10 days. After the medicine is used for 1 month, the medicine is used in a hospital to review liver, gall, spleen and pancreas and portal vein color Doppler ultrasound prompt: liver cirrhosis, splenomegaly (thickness 54mm, long diameter 160mm, internal diameter of splenic vein 11 mm), and liver function is normal; after the treatment is continued for half a year, all symptoms are improved.
The invention tests the embodiment 4 and other embodiments at the same time, and the same and similar results are obtained, which are not listed here, and the invention has good effect and stable and reliable curative effect.
7. Conclusion(s)
In conclusion, the traditional Chinese medicine composition has the advantages of scientific and reasonable compatibility of components, abundant raw materials, simple preparation method, low cost and good effect, has the effects of promoting blood circulation to remove blood stasis, softening and resolving hard mass, and relieving swelling and pain, can effectively control the size of spleen, obviously improve uncomfortable symptoms of patients, and relieve pains of the patients, and can be used for treating spleen enlargement caused by chronic viral hepatitis and liver cirrhosis compensation period. The external treatment plaster is adopted to prepare the medicine into plaster to be applied to the affected part, the medicine is directly applied to the body surface, the medicine penetrating through the absorption of local skin or a meridian system can be directly applied to the affected part, the efficacy of the medicine is directly achieved, the effects of promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation and relieving swelling and pain are exerted, the size of liver and spleen can be effectively controlled, the discomfort symptoms of patients are obviously improved, the pain of the patients is relieved, and the social and economic benefits are obvious.
The technical characteristics and key points of the invention are that the traditional Chinese medicine composition is compatible, the traditional Chinese medicine ointment is only one dosage form embodiment, and all the dosage forms which are prepared by adopting the equivalent replacement means and are applicable to taking, such as powder (pulvis), granules, pills, tablets, oral liquid, capsules, extract powder and the like, are all within the protection scope of the invention.
Claims (9)
1. The traditional Chinese medicine ointment for treating splenomegaly is characterized by being prepared from the following raw materials in parts by weight: 25-35 parts of vinegar rhizoma sparganii, 25-35 parts of vinegar rhizoma curcumae, 25-35 parts of radix trichosanthis, 25-35 parts of selfheal, 25-35 parts of calcined oyster, 15-25 parts of mirabilite, 15-25 parts of cassia twig, 5-15 parts of rheum officinale and 5-15 parts of borneol; the raw materials are uniformly mixed, and the traditional Chinese medicine composition comprises the following components in percentage by mass of 3.5:10:0.2:0.025 sesame oil, azelastone and vanillyl butyl ether are taken, firstly, the sesame oil is heated to 200 ℃ to 220 ℃, then the traditional Chinese medicine composition is added for extracting the medicine materials, the medicine is decocted until the appearance is dark brown and the interior is brown, the medicine residues are fished out, and the medicine oil is continuously heated and decocted until the temperature is 280 ℃ to 320 ℃ and the medicine oil is formed into beads by dripping water; adding red lead into the medicinal oil at uniform speed, wherein the mass ratio of the medicinal oil to the red lead is (10): 3-4, slowly pouring the mixture into cold water to soak for three days and days after the white thick smoke is exhausted and the red color disappears and the oil color changes from brown to black brown, changing water once a day to remove fire toxin, and obtaining plaster blocks; placing the plaster block into a container, heating with slow fire to 60-70deg.C, sequentially adding azepinone and vanillyl butyl ether, heating under stirring, spreading on non-woven fabric, and covering with anti-adhesive layer.
2. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 28-33 parts of vinegar common burreed rhizome, 28-33 parts of vinegar zedoary, 28-33 parts of radix trichosanthis, 28-33 parts of common selfheal fruit-spike, 28-33 parts of calcined oyster shell, 18-22 parts of mirabilite, 18-22 parts of cassia twig, 8-11 parts of rhubarb and 8-11 parts of borneol; the raw materials are uniformly mixed, and the traditional Chinese medicine composition comprises the following components in percentage by mass of 3.5:10:0.2:0.025 sesame oil, azelastone and vanillyl butyl ether are taken, firstly, the sesame oil is heated to 200 ℃ to 220 ℃, then the traditional Chinese medicine composition is added for extracting the medicine materials, the medicine is decocted until the appearance is dark brown and the interior is brown, the medicine residues are fished out, and the medicine oil is continuously heated and decocted until the temperature is 280 ℃ to 320 ℃ and the medicine oil is formed into beads by dripping water; adding red lead into the medicinal oil at uniform speed, wherein the mass ratio of the medicinal oil to the red lead is (10): 3-4, slowly pouring the mixture into cold water to soak for three days and days after the white thick smoke is exhausted and the red color disappears and the oil color changes from brown to black brown, changing water once a day to remove fire toxin, and obtaining plaster blocks; placing the plaster block into a container, heating with slow fire to 60-70deg.C, sequentially adding azepinone and vanillyl butyl ether, heating under stirring, spreading on non-woven fabric, and covering with anti-adhesive layer.
3. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 25 parts of vinegar common burreed rhizome, 25 parts of vinegar zedoary, 25 parts of radix trichosanthis, 25 parts of common selfheal fruit-spike, 25 parts of calcined oyster shell, 15 parts of mirabilite, 15 parts of cassia twig, 5 parts of rheum officinale and 5 parts of borneol.
4. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 28 parts of vinegar rhizoma sparganii, 28 parts of vinegar rhizoma curcumae, 28 parts of radix trichosanthis, 28 parts of selfheal, 28 parts of calcined oyster, 18 parts of mirabilite, 18 parts of cassia twig, 8 parts of rheum officinale and 8 parts of borneol.
5. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 30 parts of vinegar common burreed rhizome, 30 parts of vinegar zedoary, 30 parts of radix trichosanthis, 30 parts of common selfheal fruit-spike, 30 parts of calcined oyster shell, 20 parts of mirabilite, 20 parts of cassia twig, 10 parts of rheum officinale and 10 parts of borneol.
6. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 33 parts of vinegar common burreed rhizome, 33 parts of vinegar zedoary, 33 parts of radix trichosanthis, 33 parts of common selfheal fruit-spike, 33 parts of calcined oyster shell, 23 parts of mirabilite, 23 parts of cassia twig, 13 parts of rhubarb and 13 parts of borneol.
7. The traditional Chinese medicine ointment for treating splenomegaly according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 35 parts of vinegar common burreed rhizome, 35 parts of vinegar zedoary, 35 parts of radix trichosanthis, 35 parts of common selfheal fruit-spike, 35 parts of calcined oyster shell, 25 parts of mirabilite, 25 parts of cassia twig, 15 parts of rhubarb and 15 parts of borneol.
8. The Chinese medicinal ointment for treating splenomegaly according to any one of claims 1 to 7, wherein the splenomegaly comprises liver cirrhosis compensation and splenomegaly caused by chronic viral hepatitis.
9. The Chinese medicinal ointment according to any one of claims 1 to 7, wherein the Chinese medicinal ointment is a pharmaceutically acceptable ointment, plaster, gel, paste, film coating agent, cataplasm, transdermal patch, topical liquid preparation, skin external film preparation, topical aerosol or topical tincture in any dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310448182.8A CN116474058B (en) | 2023-04-24 | 2023-04-24 | Traditional Chinese medicine ointment for treating spleen enlargement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310448182.8A CN116474058B (en) | 2023-04-24 | 2023-04-24 | Traditional Chinese medicine ointment for treating spleen enlargement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116474058A true CN116474058A (en) | 2023-07-25 |
| CN116474058B CN116474058B (en) | 2024-06-14 |
Family
ID=87220908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310448182.8A Active CN116474058B (en) | 2023-04-24 | 2023-04-24 | Traditional Chinese medicine ointment for treating spleen enlargement |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116474058B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785609A (en) * | 2018-08-24 | 2018-11-13 | 浏阳市中医医院 | A kind of Chinese medicine composition for treating hepatic sclerosis splenomegaly |
-
2023
- 2023-04-24 CN CN202310448182.8A patent/CN116474058B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785609A (en) * | 2018-08-24 | 2018-11-13 | 浏阳市中医医院 | A kind of Chinese medicine composition for treating hepatic sclerosis splenomegaly |
Non-Patent Citations (1)
| Title |
|---|
| 党中勤: "中药外敷为主治疗肝硬化门脉高压症64例", 中国中西医结合消化杂志, vol. 10, no. 02, 25 April 2002 (2002-04-25), pages 123 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116474058B (en) | 2024-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102188685B (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101274024A (en) | Pharmaceutical compositions for curing toothache | |
| CN102657795A (en) | Traditional Chinese medicine preparation for promoting postoperative incision healing | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN102872362B (en) | Traditional Chinese medicine for treating chronic cholecystitis | |
| CN116474058B (en) | Traditional Chinese medicine ointment for treating spleen enlargement | |
| CN104547736A (en) | Medicine for treating goiter | |
| CN105434739A (en) | Traditional Chinese medicine composition for treating chalazia and preparation method thereof | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
| CN101085303A (en) | Oral administration traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN104825779A (en) | Traditional Chinese medicine oral aerosol | |
| CN104352667A (en) | Medicine for treating nonspecific vaginitis and preparation method | |
| CN102764325B (en) | Chinese medicinal composition for dispelling rheumatism and relieving pain | |
| CN109833371B (en) | Traditional Chinese medicine composition for treating constipation after hemorrhoids and fistula operation and preparation method and application thereof | |
| CN103041362A (en) | Drug for treating rheumatism and rheumatoid and preparation method thereof | |
| CN113491739B (en) | Pain-relieving and stasis-eliminating traditional Chinese medicine for treating endometriosis and preparation method thereof | |
| CN105232661A (en) | Traditional Chinese medicine composition for treating mastitis and preparation method thereof | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN105079661A (en) | Traditional Chinese medicine composition for treating hemafecia | |
| CN105288436A (en) | Medicament for treatment of chronic eczema | |
| CN104645224A (en) | Traditional Chinese medicine preparation for treating costal chondritis | |
| CN106309926A (en) | Composition prepared from bee products and medical and edible dual-purpose food and used for treating gastritis and gastric ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |